Details of the Drug

General Information of Drug (ID: DMPSB8F)

Drug Name

MEPTAZINOL

Synonyms

MEPTAZINOL HYDROCHLORIDE; 59263-76-2; Meptazinol HCl; Meptazinol (hydrochloride); 3-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Meptazinol hydrochloride [USAN]; EINECS 261-683-0; WY-22811 hydrochloride; IL-22811 hydrochloride; WY 22811; IL 22811; 3-(3-ethyl-1-methylazepan-3-yl)phenol hydrochloride; m-(3-Ethyl-1-methyl-hexahydro-1H-azepin-3-yl)phenol hydrochloride; m-(3-Ethylhexahydro-1-methyl-1H-azepin-3-yl)phenol hydrochloride; Phenol, m-(3-ethyl-1-methyl-hexahydro-1H-azepin-3-yl)-, hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

233.35

Logarithm of the Partition Coefficient (xlogp)

3.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Clearance: The drug present in the plasma can be removed from the body at the rate of 28 mL/min/kg [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.7 hours [2]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 63.525 micromolar/kg/day [3]
Unbound Fraction: The unbound fraction of drug in plasma is 0.73% [2]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.3 L/kg [2]

Chemical Identifiers

Formula: C15H23NO
IUPAC Name: 3-(3-ethyl-1-methylazepan-3-yl)phenol
Canonical SMILES: CCC1(CCCCN(C1)C)C2=CC(=CC=C2)O
InChI: InChI=1S/C15H23NO/c1-3-15(9-4-5-10-16(2)12-15)13-7-6-8-14(17)11-13/h6-8,11,17H,3-5,9-10,12H2,1-2H3
InChIKey: JLICHNCFTLFZJN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 41049
ChEBI ID: CHEBI:91484
CAS Number: 54340-58-8
DrugBank ID: DB13478
TTD ID: D0S5YC

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cholinesterase (BCHE)	TTEB0GD	CHLE_HUMAN	Inhibitor	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
5	Profiling the Tox21 Chemical Collection for Acetylcholinesterase Inhibition. Environ Health Perspect. 2021 Apr;129(4):47008. doi: 10.1289/EHP6993. Epub 2021 Apr 12.